Fig. 8: Protective potential of an optimized poly-antigenic LV as a booster against Mtb. | Mucosal Immunology

Fig. 8: Protective potential of an optimized poly-antigenic LV as a booster against Mtb.

From: A lentiviral vector expressing a dendritic cell-targeting multimer induces mucosal anti-mycobacterial CD4+ T-cell immunity

Fig. 8

a Timeline of the prime-boost-challenge performed in C57BL/6 mice (n = 5–8 mice/group). b Mtb burden as quantitated by CFU counting in the lungs of BCG::ESX-1Mmar-primed and LV::S40-HAPEHR-20-boosted mice on week 5 post challenge. c Whole-lung section of the left lobe and d quantification of the number and size of lung granulomatous lesions per mouse in each experimental group. e Mtb burden quantified by CFU counting in the lungs of BCG-primed and LV::S40-HAPEHR-20-boosted C57BL/6 mice following the timeline indicated in a, but using Danish BCG for the prime immunization and i.n. Mtb challenge. The pooled results from two independent experiments are shown (n = 6–8 mice/group in each experiment). The significance of the differences was determined using the Mann–Whitney test. ns not significant.

Back to article page